| Osteoprotegerin: multiple partners for multiple functions M Baud’huin, L Duplomb, S Teletchea, F Lamoureux, C Ruiz-Velasco, ... Cytokine & growth factor reviews 24 (5), 401-409, 2013 | 173 | 2013 |
| New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? SK Tat, JP Pelletier, CR Velasco, M Padrines, J Martel-Pelletier The Keio journal of medicine 58 (1), 29-40, 2009 | 167 | 2009 |
| Key roles of the OPG–RANK–RANKL system in bone oncology M Baud’huin, L Duplomb, CR Velasco, Y Fortun, D Heymann, M Padrines Expert review of anticancer therapy 7 (2), 221-232, 2007 | 110 | 2007 |
| Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient KG Phillips, CR Velasco, J Li, A Kolatkar, M Luttgen, K Bethel, B Duggan, ... Frontiers in oncology 2, 72, 2012 | 104 | 2012 |
| Proteases and bone remodelling S Georges, CR Velasco, V Trichet, Y Fortun, D Heymann, M Padrines Cytokine & growth factor reviews 20 (1), 29-41, 2009 | 73 | 2009 |
| Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry E Gerdtsson, M Pore, JA Thiele, AS Gerdtsson, PD Malihi, R Nevarez, ... Convergent science physical oncology 4 (1), 015002, 2018 | 69 | 2018 |
| Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer PD Malihi, RP Graf, A Rodriguez, N Ramesh, J Lee, R Sutton, R Jiles, ... Clinical Cancer Research 26 (15), 4143-4153, 2020 | 55 | 2020 |
| Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients C Ruiz, J Li, MS Luttgen, A Kolatkar, JT Kendall, E Flores, Z Topp, ... Physical biology 12 (1), 016008, 2015 | 46 | 2015 |
| Anti-metastatic properties of a marine bacterial exopolysaccharide-based derivative designed to mimic glycosaminoglycans D Heymann, C Ruiz-Velasco, J Chesneau, J Ratiskol, C Sinquin, ... Molecules 21 (3), 309, 2016 | 36 | 2016 |
| Effects of a sulfated exopolysaccharide produced by Altermonas infernus on bone biology C Ruiz Velasco, M Baud'Huin, C Sinquin, M Maillasson, D Heymann, ... Glycobiology 21 (6), 781-795, 2011 | 35 | 2011 |
| Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient L Welter, L Xu, D McKinley, AE Dago, RK Prabakar, S Restrepo-Vassalli, ... Molecular Case Studies 6 (6), a005819, 2020 | 29 | 2020 |
| Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption M Baud’Huin, C Ruiz-Velasco, G Jego, C Charrier, N Gasiunas, ... European Journal of Cell Biology 90 (1), 49-57, 2011 | 29 | 2011 |
| Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis PD Malihi, M Morikado, L Welter, ST Liu, ET Miller, RM Cadaneanu, ... Convergent science physical oncology 4 (1), 015003, 2018 | 24 | 2018 |
| Large extracellular vesicle characterization and association with circulating tumor cells in metastatic castrate resistant prostate cancer AS Gerdtsson, SM Setayesh, PD Malihi, C Ruiz, A Carlsson, R Nevarez, ... Cancers 13 (5), 1056, 2021 | 23 | 2021 |
| Proteoglycans on bone tumor development CR Velasco, S Colliec-Jouault, F Redini, D Heymann, M Padrines Drug discovery today 15 (13-14), 553-560, 2010 | 23 | 2010 |
| Preanalytical variables for the genomic assessment of the cellular and acellular fractions of the liquid biopsy in a cohort of breast cancer patients SN Shishido, L Welter, M Rodriguez-Lee, A Kolatkar, L Xu, C Ruiz, ... The Journal of Molecular Diagnostics 22 (3), 319-337, 2020 | 20 | 2020 |
| Platelet-coated circulating tumor cells are a predictive biomarker in patients with metastatic castrate-resistant prostate cancer S Chai, N Matsumoto, R Storgard, CC Peng, A Aparicio, B Ormseth, ... Molecular Cancer Research 19 (12), 2036-2045, 2021 | 19 | 2021 |
| Bone cancer: progression and therapeutic approaches D Heymann Academic Press, 2009 | 19 | 2009 |
| Phase Ib study of enzalutamide with or without sorafenib in patients with advanced hepatocellular carcinoma JJ Harding, RK Kelley, B Tan, M Capanu, GK Do, J Shia, JF Chou, ... The oncologist 25 (12), e1825-e1836, 2020 | 14 | 2020 |
| Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. B Brounais, C Ruiz, J Rousseau, F Lamoureux, F Blanchard, D Heymann, ... Recent Patents on Anti-Cancer Drug Discovery 3 (3), 178-186, 2008 | 13 | 2008 |
